These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 19945004)

  • 1. An analysis of the long-term safety data of repeat administrations of botulinum neurotoxin type A-ABO for the treatment of glabellar lines.
    Cohen JL; Schlessinger J; Cox SE; Lin X;
    Aesthet Surg J; 2009 Nov; 29(6 Suppl):S43-9. PubMed ID: 19945004
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An analysis of safety data from five phase III clinical trials on the use of botulinum neurotoxin type A-ABO for the treatment of glabellar lines.
    Rubin M; Dover J; Maas C; Nestor M
    Aesthet Surg J; 2009 Nov; 29(6 Suppl):S50-6. PubMed ID: 19945005
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An analysis of efficacy data from four phase III studies of botulinum neurotoxin type A-ABO for the treatment of glabellar lines.
    Baumann L; Brandt FS; Kane MA; Donofrio LM
    Aesthet Surg J; 2009 Nov; 29(6 Suppl):S57-65. PubMed ID: 19945006
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An evaluation of neutralizing antibody induction during treatment of glabellar lines with a new US formulation of botulinum neurotoxin type A.
    Lawrence I; Moy R
    Aesthet Surg J; 2009 Nov; 29(6 Suppl):S66-71. PubMed ID: 19945007
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Botulinum neurotoxin type A-ABO (Dysport): clinical indications and practice guide.
    Matarasso A; Shafer D
    Aesthet Surg J; 2009 Nov; 29(6 Suppl):S72-9. PubMed ID: 19945008
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term safety of repeated administrations of a new formulation of botulinum toxin type A in the treatment of glabellar lines: interim analysis from an open-label extension study.
    Monheit GD; Cohen JL;
    J Am Acad Dermatol; 2009 Sep; 61(3):421-5. PubMed ID: 19577326
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Time to onset of response of abobotulinumtoxina in the treatment of glabellar lines: a subset analysis of phase 3 clinical trials of a new botulinum toxin type A.
    Schlessinger J; Monheit G; Kane MA; Mendelsohn N
    Dermatol Surg; 2011 Oct; 37(10):1434-42. PubMed ID: 21745254
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term safety and efficacy of a new botulinum toxin type A in treating glabellar lines.
    Moy R; Maas C; Monheit G; Huber MB;
    Arch Facial Plast Surg; 2009; 11(2):77-83. PubMed ID: 19289677
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term safety of abobotulinumtoxinA for the treatment of glabellar lines: results from a 36-month, multicenter, open-label extension study.
    Schlessinger J; Dover JS; Joseph J; Monheit G; Nelson DB; Albright CD; Axford-Gatley RA; Cohen JL;
    Dermatol Surg; 2014 Feb; 40(2):176-83. PubMed ID: 24372978
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety, Tolerability, and Efficacy of Repeat-Dose Injections of IncobotulinumtoxinA in the Treatment of Upper Facial Lines: Results from a Prospective, Open-Label, Phase III Study.
    Fischer T; Sattler G; Prager W; Rzany B; Pavicic T; Gauglitz G; Weissenberger P; Riaz S
    J Drugs Dermatol; 2020 May; 19(5):461-469. PubMed ID: 32484631
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and Safety of AbobotulinumtoxinA for the Treatment of Glabellar Lines in Chinese Patients: A Pivotal, Phase 3, Randomized, Double-Blind and Open-Label Phase Study.
    Wu Y; Fang F; Lai W; Li C; Li L; Liu Q; Lu J; Pang X; Sun J; Shi X; Picaut P; Prygova I; Andriopoulos B; Sun Q
    Aesthetic Plast Surg; 2023 Feb; 47(1):351-364. PubMed ID: 36536093
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An open-label, randomized, 64-week study repeating 10- and 20-U doses of botulinum toxin type A for treatment of glabellar lines in Japanese subjects.
    Kawashima M; Harii K
    Int J Dermatol; 2009 Jul; 48(7):768-76. PubMed ID: 19490208
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized, placebo-controlled study of a new botulinum toxin type a for treatment of glabellar lines: efficacy and safety.
    Brandt F; Swanson N; Baumann L; Huber B
    Dermatol Surg; 2009 Dec; 35(12):1893-901. PubMed ID: 19549186
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term results for incobotulinumtoxinA in the treatment of glabellar frown lines.
    Rzany B; Flynn TC; Schlöbe A; Heinz M; Harrington L
    Dermatol Surg; 2013 Jan; 39(1 Pt 1):95-103. PubMed ID: 23190342
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Does Increasing the Dose of Abobotulinumtoxina Impact the Duration of Effectiveness for the Treatment of Moderate to Severe Glabellar Lines?
    Joseph JH; Eaton LL; Robinson J; Pontius A; Williams EF
    J Drugs Dermatol; 2016 Dec; 15(12):1544-1549. PubMed ID: 29106437
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The science and manufacturing behind botulinum neurotoxin type A-ABO in clinical use.
    Wortzman MS; Pickett A
    Aesthet Surg J; 2009 Nov; 29(6 Suppl):S34-42. PubMed ID: 19945003
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of variable-dose treatment with a new U.S. Botulinum Toxin Type A (Dysport) for correction of moderate to severe glabellar lines: results from a phase III, randomized, double-blind, placebo-controlled study.
    Kane MAC; Brandt F; Rohrich RJ; Narins RS; Monheit GD; Huber MB;
    Plast Reconstr Surg; 2009 Nov; 124(5):1619-1629. PubMed ID: 19584772
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Botulinum toxin: examining duration of effect in facial aesthetic applications.
    Flynn TC
    Am J Clin Dermatol; 2010; 11(3):183-99. PubMed ID: 20369902
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Botulinum toxin for glabellar lines: a review of the efficacy and safety of currently available products.
    Dessy LA; Fallico N; Mazzocchi M; Scuderi N
    Am J Clin Dermatol; 2011 Dec; 12(6):377-88. PubMed ID: 21877763
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Remodeling of periorbital, temporal, glabellar, and crow's feet areas with hyaluronic acid and botulinum toxin.
    Beer KR; Julius H; Dunn M; Wilson F
    J Cosmet Dermatol; 2014 Jun; 13(2):143-50. PubMed ID: 24910278
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.